P2 purinergic receptors regulate the progression of colorectal cancer.

IF 2.4 4区医学 Q2 NEUROSCIENCES

Purinergic Signalling Pub Date : 2025-08-01 Epub Date: 2023-12-28 DOI:10.1007/s11302-023-09983-6

Wen-Jun Zhang, Li-Peng Zhang, Si-Jian Lin, Cheng-Yi Wang, Yi-Guan Le

{"title":"P2 purinergic receptors regulate the progression of colorectal cancer.","authors":"Wen-Jun Zhang, Li-Peng Zhang, Si-Jian Lin, Cheng-Yi Wang, Yi-Guan Le","doi":"10.1007/s11302-023-09983-6","DOIUrl":null,"url":null,"abstract":"<p><p>More and more studies have revealed that P2 purinergic receptors play a key role in the progression of colorectal cancer (CRC). P2X and P2Y purinergic receptors can be used as promoters and regulators of CRC and play a dual role in the progression of CRC. CRC microenvironment is rich in ATP and its cleavage products (ADP, AMP, Ado), which act as activators of P2X and P2Y purinergic receptors. The activation of P2X and P2Y purinergic receptors regulates the progression of CRC mainly by regulating the function of immune cells and mediating different signal pathways. In this paper, we focus on the specific mechanisms and functional roles of P2X7, P2Y12, and P2Y2 receptors in the growth and progression of CRC. The antagonistic effects of these selective antagonists of P2X purinergic receptors on the growth, invasion, and metastasis of CRC were further discussed. Moreover, different studies have reported that P2X7 receptor can be used as an effective predictor of patients with CRC. All these indicate that P2 purinergic receptors are a key regulator of CRC. Therefore, antagonizing P2 purinergic receptors may be an innovative treatment for CRC.</p>","PeriodicalId":20952,"journal":{"name":"Purinergic Signalling","volume":" ","pages":"767-780"},"PeriodicalIF":2.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454802/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Purinergic Signalling","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11302-023-09983-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

More and more studies have revealed that P2 purinergic receptors play a key role in the progression of colorectal cancer (CRC). P2X and P2Y purinergic receptors can be used as promoters and regulators of CRC and play a dual role in the progression of CRC. CRC microenvironment is rich in ATP and its cleavage products (ADP, AMP, Ado), which act as activators of P2X and P2Y purinergic receptors. The activation of P2X and P2Y purinergic receptors regulates the progression of CRC mainly by regulating the function of immune cells and mediating different signal pathways. In this paper, we focus on the specific mechanisms and functional roles of P2X7, P2Y12, and P2Y2 receptors in the growth and progression of CRC. The antagonistic effects of these selective antagonists of P2X purinergic receptors on the growth, invasion, and metastasis of CRC were further discussed. Moreover, different studies have reported that P2X7 receptor can be used as an effective predictor of patients with CRC. All these indicate that P2 purinergic receptors are a key regulator of CRC. Therefore, antagonizing P2 purinergic receptors may be an innovative treatment for CRC.

查看原文本刊更多论文

P2 嘌呤能受体调控结直肠癌的进展。

越来越多的研究发现，P2嘌呤能受体在结直肠癌（CRC）的进展中起着关键作用。P2X 和 P2Y 嘌呤能受体可作为 CRC 的促进因子和调节因子，在 CRC 的进展过程中发挥双重作用。CRC 微环境中含有丰富的 ATP 及其裂解产物（ADP、AMP、Ado），它们是 P2X 和 P2Y 嘌呤能受体的激活剂。P2X 和 P2Y 嘌呤能受体的激活主要通过调节免疫细胞的功能和介导不同的信号通路来调控 CRC 的进展。本文重点研究了 P2X7、P2Y12 和 P2Y2 受体在 CRC 生长和进展过程中的具体机制和功能作用。并进一步讨论了这些 P2X 嘌呤能受体选择性拮抗剂对 CRC 生长、侵袭和转移的拮抗作用。此外，有不同的研究报告称，P2X7 受体可作为预测 CRC 患者的有效指标。所有这些都表明，P2嘌呤能受体是 CRC 的一个关键调节因子。因此，拮抗P2嘌呤能受体可能是治疗CRC的一种创新方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Purinergic Signalling 医学-神经科学

CiteScore

6.60

自引率

17.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Nucleotides and nucleosides are primitive biological molecules that were utilized early in evolution both as intracellular energy sources and as extracellular signalling molecules. ATP was first identified as a neurotransmitter and later as a co-transmitter with all the established neurotransmitters in both peripheral and central nervous systems. Four subtypes of P1 (adenosine) receptors, 7 subtypes of P2X ion channel receptors and 8 subtypes of P2Y G protein-coupled receptors have currently been identified. Since P2 receptors were first cloned in the early 1990’s, there is clear evidence for the widespread distribution of both P1 and P2 receptor subtypes in neuronal and non-neuronal cells, including glial, immune, bone, muscle, endothelial, epithelial and endocrine cells.